Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 6, 2019

Primary Completion Date

August 18, 2021

Study Completion Date

September 14, 2022

Conditions
Primary Hemophagocytic Lymphohistiocytosis
Interventions
DRUG

Emapalumab

Emapalumab will be administered by intravenous infusion, twice weekly.

Trial Locations (27)

14186

Karolinska University Hospital Huddinge, Stockholm

16147

Istituto Giannina Gaslini, Genova

19803

Alfred I. duPont Hospital for Children - Nemours Center for Cancer and Blood Disorders - Division of Pediatric Hematology Oncology, Wilmington

20246

Universitätsklinikum Eppendorf, Hamburg

20900

Fondazione MBBM, Ospedale San Gerardo, Monza

28009

Hospital Universitario Niño Jesús, Madrid

30329

Children's Healthcare of Atlanta, Atlanta

37126

Ospedale della Donna e del Bambino, Verona

45147

Universitätsklinikum Essen, Essen

45229

Cincinnati Children's Hospital, Cincinnati

49503

Spectrum Health Helen DeVos Children's Hospital, Grand Rapids

77030

Texas Children's Hospital - Feigin Center, Houston

79106

Medical Center- University of Freiburg, Freiburg im Breisgau

85016

Phoenix Children Hospital, Phoenix

90027

Children's Hospital Los Angeles, Los Angeles

98109

Seattle Children's Hospital, Seattle

80045-7106

Children's Hospital Colorado, Aurora

02215

Dana-Farber Cancer Institute (DFCI), Boston

QC H3T 1C5

Hopital Ste-Justine Research Center, Montreal

ON M5G 1X8

Hospital for Sick Children, Toronto

V6H 3V4

Children's and Women's Health Centre of British Columbia, Vancouver

00165

Ospedale Pediatrico Bambino Gesù, Rome

08035

Hospital Universitario Vall d'Hebron, Barcelona

CH-8032

University Children's Hospital Zurich, Zurich

LS1 3EX

Leeds Children's Hospital, Leeds

WC1N 3JH

Great Ormond Street Hospital, London

M13 9WL

Royal Manchester Children's Hospital, Manchester

Sponsors
All Listed Sponsors
lead

Swedish Orphan Biovitrum

INDUSTRY